2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Biological Processes, Microbiome, Clinical Practice (Health Services and Quality), Practice Models, Quality Improvement, Quality of Care, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, GVHD, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, MPN, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

2442 Comparable outcomes but distinct toxicity profiles of flu/cy/ATG versus bu/cy/ATG conditioning in haploidentical transplantation for severe aplastic anemia

Xianfu Sheng, MD, Nanxi Dong, MD2, Yingying Shen3, Wenbin Liu, MD,PhD4, Baodong Ye, MD, PhD5, Yu Zhang Jr, MD6
1 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
2 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
3 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
4 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
5 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
6 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China

Severe aplastic anemia (SAA) is a life-threatening bone marrow failure syndrome for which allogeneic hematopoietic stem cell transplantation (HSCT) is curative. Haploidentical HSCT (haplo-HSCT) provides rapid donor availability, but graft rejection, graft-versus-host disease (GVHD), and regimen-related toxicity remain major concerns. Within the granulocyte colony-stimulating factor (G-CSF)/antithymocyte globulin (ATG)-based Beijing platform, busulfan/cyclophosphamide/ATG (Bu/Cy/ATG) is commonly recommended to reduce rejection, whereas fludarabine/cyclophosphamide/ATG (Flu/Cy/ATG) is often used in practice to mitigate busulfan-related toxicity. Direct comparative data between these conditioning strategies in haplo-HSCT for SAA are limited.
We retrospectively analyzed 76 consecutive patients with SAA who underwent first haplo-HSCT at our institution from January 2019 through December 2022. This study was registered at Chinese Clinical Trial Registry (ChiCTR2600128918). Forty-six patients received Flu/Cy/ATG and 30 received Bu/Cy/ATG. Flu/Cy/ATG used fludarabine (total 150 mg/m2), cyclophosphamide (total 120 mg/kg), and rabbit ATG (total 10mg/kg); Bu/Cy/ATG used busulfan (total 6.4mg/kg), cyclophosphamide (total 200 mg/kg), and rabbit ATG (total 10mg/kg). GVHD prophylaxis included cyclosporine, mycophenolate mofetil, and short-course methotrexate. Primary endpoints were overall survival (OS) and GVHD-free, failure-free survival (GFFS); secondary endpoints included engraftment, GVHD, infections, organ toxicity, and other safety events.
Baseline characteristics were generally balanced between groups. Median age was 30.5 years in the Flu/Cy/ATG group and 30 years in the Bu/Cy/ATG group (P=0.941). Disease severity, prior therapy, HLA mismatch, donor-specific antibody positivity, HCT-CI, graft source, mononuclear cell dose, and CD34+ cell dose were also comparable.
Engraftment was rapid and similar between groups. Median neutrophil recovery was 11 days in both (ranges 9–23 vs 8–29; P=0.962), and platelet recovery was 13 days in both (ranges 10–72 vs 10–70; P=0.997). Cumulative day+30 neutrophil engraftment (97.8% vs 96.7%, P=0.396) and day+100 platelet engraftment (95.7% vs 96.7%, P=0.758) were comparable. No primary graft failure occurred; secondary failure occurred in 2 (4.4%) vs 1 (3.4%) patient (P=1.000).
GVHD outcomes did not differ significantly between conditioning groups. The cumulative incidences of grade II-IV acute GVHD were 26.1% after Flu/Cy/ATG and 23.3% after Bu/Cy/ATG (P=0.789), and the corresponding incidences of grade III-IV acute GVHD were 10.9% and 16.7% (P=0.485). The 5-year cumulative incidences of chronic GVHD were 24.4% and 21.4% (P=0.739), respectively, and moderate-severe chronic GVHD occurred in 7.3% and 3.6% (P=0.502).
With a median follow-up of approximately 5 years among survivors, the estimated 5-year OS was 77.3% after Flu/Cy/ATG and 90.0% after Bu/Cy/ATG (P=0.196); 5-year GFFS was 62.3% and 76.7%, respectively (P=0.246). In multivariable analysis, conditioning regimen was not independently associated with OS or GFFS. Graft failure was associated with OS (HR 33.545, 95% CI 6.545-171.919; P<0.001) and GFFS (HR 10.572, 95% CI 2.815-39.704; P<0.001), while grade II-IV acute GVHD and moderate-severe chronic GVHD were associated with loss of GFFS.
Despite comparable efficacy endpoints, toxicity profiles differed. Flu/Cy/ATG was associated with more pneumonia (34.8% vs 10.0%; P=0.015) and EBV reactivation requiring rituximab (26.1% vs 6.7%; P=0.033). CMV reactivation was numerically higher after Flu/Cy/ATG (34.8% vs 16.7%; P=0.084), but CMV disease was rare. In contrast, Bu/Cy/ATG was associated with more thrombotic microangiopathy (16.7% vs 2.2%; P=0.027) and numerically higher cardiac dysfunction (16.7% vs 4.3%; P=0.103) and hemorrhagic cystitis (36.7% vs 19.6%; P=0.097). Ten deaths occurred after Flu/Cy/ATG and 3 after Bu/Cy/ATG, with infection-related mortality predominating after Flu/Cy/ATG.
In this single-center real-world cohort, Flu/Cy/ATG and Bu/Cy/ATG conditioning produced comparable engraftment, GVHD, OS, and GFFS after haplo-HSCT for SAA, but with distinct toxicity patterns. These findings support risk-adapted conditioning selection: Flu/Cy/ATG may be reasonable when busulfan-related toxicity or fertility preservation is a major concern, provided infection monitoring is stringent, whereas Bu/Cy/ATG may be favored when rejection risk is paramount or infection risk is high.

Xianfu Sheng, MD: No relevant conflicts of interest to declare.